#China #Shanghai #ADC technology #WuXi XDC #AbTis

WuXi XDC and AbTis Announce a Strategic Partnership for Next-Generation ADCs

WuXi XDC Cayman Inc., a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), has officially announced a strategic partnership with AbTis, a leading biotechnology company in South Korea specializing in antibody-drug conjugates (ADCs).

Partnership Overview

The signing of a Memorandum of Understanding (MOU) marks a significant collaboration aimed at revolutionizing the ADC landscape. This partnership will unite AbTis’ proprietary AbClick® platform, known for its site-selective conjugation technology, with WuXi XDC’s comprehensive development and manufacturing capabilities. By combining their strengths, the two companies aim to streamline ADC therapeutic innovations and broaden their service offerings to global clients.

Technological Integration

At the core of this agreement is the inclusion of AbTis' cutting-edge conjugation technologies into WuXi XDC’s existing portfolio. The AbClick® platform utilizes affinity peptide-assisted linkers to enable precise and efficient conjugation of drugs to antibodies. This integration is expected to enhance WuXi XDC’s ability to provide comprehensive solutions that not only hasten preclinical candidate selection but also support accelerated timelines in the development of next-generation ADCs.

Dr. Marie Zhu, CTO of WuXi XDC, emphasized the importance of this collaboration, stating, "This partnership exemplifies our dedication to fostering innovation through strategic alliances. The addition of AbTis' advanced technologies will augment our bioconjugation suite, thus benefitting our clients with a broader array of solutions for developing advanced therapeutics."

Benefits to Global Clients

Both companies share a vision for advancing the ADC field through enhanced technological collaboration. By working together, they aim to unlock new market opportunities and innovations for their clients around the world. WuXi XDC will facilitate potential partnerships between AbTis and its expansive client network, promoting the widespread adoption of innovative ADC solutions within the bioconjugate drug industry.

Dr. Tae Dong Han, CEO of AbTis, expressed excitement about the partnership, noting that "Joining forces with WuXi XDC is a significant milestone for AbTis as we look to extend the reach of our technology. By harnessing WuXi XDC's expansive network and expertise, we are poised to enhance the accessibility and impact of our revolutionary lid-selective conjugation technologies."

Conclusion

In conclusion, the collaboration between WuXi XDC and AbTis represents a promising advancement in the development of ADCs. As they work together to innovate and improve the therapeutic landscape, patients worldwide stand to benefit from the rapid development of next-generation bioconjugate therapies. This partnership underscores a shared commitment to innovation in the biopharmaceutical industry, aiming to deliver better treatment options for patients suffering from various conditions.

For more information on WuXi XDC, visit wuxixdc.com. To learn more about AbTis and its technologies, visit abtis.co.kr.